Related Experiment Video

Updated: Jun 22, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Combination effect between bortezomib and tumor necrosis factor alpha on gefitinib-resistant non-small cell lung

Sojiro Kusumoto1, Tomohide Sugiyama, Koichi Ando

  • 1Division of Allergology and Respiratory Medicine, Department of Internal Medicine, Showa University, Shinagawa-ku, Tokyo 142-8555, Japan.

Anticancer Research
|June 17, 2009
PubMed

Insights

Gefitinib-resistant non-small cell lung cancer (NSCLC) may be treated by combining bortezomib and tumor necrosis factor-alpha (TNF-alpha). This combination demonstrated synergistic cytotoxicity against resistant NSCLC cells, offering a potential new therapeutic strategy.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Acquired resistance to gefitinib complicates non-small cell lung cancer (NSCLC) treatment.
  • Gefitinib-resistant NSCLC cells (PC-9/ZD2001) exhibit collateral sensitivity to tumor necrosis factor-alpha (TNF-alpha).
  • Bortezomib, a proteasome inhibitor, potentiates TNF-alpha-induced cell death.

Purpose of the Study:

  • To investigate the synergistic cytotoxic effect of combining bortezomib and TNF-alpha against gefitinib-resistant NSCLC cells.
  • To explore the underlying mechanisms of this combination therapy's efficacy.

Main Methods:

  • Establishment of a gefitinib-resistant NSCLC cell line (PC-9/ZD2001).
  • Evaluation of drug combination effects using MTT assay.
  • Analysis of molecular mechanisms via immunoblotting to assess IkappaB degradation.

Main Results:

  • The combination of bortezomib and TNF-alpha exhibited synergistic cytotoxicity in NSCLC cell lines with acquired or intrinsic gefitinib resistance.
  • This synergistic effect was not observed in gefitinib-sensitive NSCLC cells.
  • Bortezomib was found to inhibit TNF-alpha-induced IkappaB degradation across all tested cell lines.

Conclusions:

  • The combination of bortezomib and TNF-alpha represents a promising strategy to overcome gefitinib resistance in non-small cell lung cancer.
  • This therapeutic approach targets specific resistance mechanisms, potentially improving treatment outcomes for NSCLC patients.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...